{"id":"W2996535743","doi":"10.3233/blc-190252","title":"Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial","year":2019,"lang":"en","type":"article","venue":"Bladder Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Ipsen; Incyte; Astellas Pharma; Clovis Oncology; Exelixis; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Docetaxel; Ramucirumab; Medicine; Internal medicine; Placebo; Hazard ratio; Subgroup analysis; Oncology; Chemotherapy; Adverse effect; Progression-free survival; Urology; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001711483,0.0004919035,0.001008471,0.0001974085,0.00007054563,0.00006819987,0.0001490806,0.0001662578,0.002877655],"category_scores_gemma":[0.00001695808,0.0002794346,0.0002500255,0.0007704877,0.0001532271,0.0001547736,0.00003032633,0.0003389858,0.00001388978],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002581534,"about_ca_system_score_gemma":0.0005757317,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004206771,"about_ca_topic_score_gemma":0.006656374,"domain_scores_codex":[0.9974665,0.0001053516,0.0005354163,0.0008454692,0.0005605919,0.0004866406],"domain_scores_gemma":[0.9986643,0.0001376129,0.0002113179,0.0007121174,0.00008708033,0.0001875607],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5149277,0.0008582533,0.4690419,0.00005526405,0.001490153,0.0000720063,0.003170568,0.0000587785,0.001171388,0.000001617079,0.0001433597,0.00900907],"study_design_scores_gemma":[0.5322753,0.003747975,0.4471123,0.0003215265,0.002536817,0.000008034291,0.0005104314,0.00156788,0.007724505,0.00001802251,0.003510983,0.0006662333],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919558,0.00205614,0.000145234,0.001076475,0.0002565809,0.003852205,0.0002929389,0.00006019253,0.0003044384],"genre_scores_gemma":[0.9946009,0.0001377019,0.0003907544,0.001808558,0.0006429517,0.001389687,0.00006007759,0.0000909532,0.000878453],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02192958,"threshold_uncertainty_score":0.9999658,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01650419932740946,"score_gpt":0.2940631657067778,"score_spread":0.2775589663793683,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}